Phase II study of neoadjuvant imatinib in large gastrointestinal stromal tumours of the stomach

Yukinori Kurokawa, Han Kwang Yang, Haruhiko Cho, Min Hee Ryu, Toru Masuzawa, Sook Ryun Park, Sohei Matsumoto, Hyuk Joon Lee, Hiroshi Honda, Oh Kyoung Kwon, Takashi Ishikawa, Kyung Hee Lee, Kazuhito Nabeshima, Seong Ho Kong, Toshio Shimokawa, Jeong Hwan Yook, Yuichiro Doki, Seock Ah Im, Seiichi Hirota, Seokyung HahnToshirou Nishida, Yoon Koo Kang

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background:Gastrointestinal stromal tumours (GISTs) with high-risk features have poor prognosis even if adjuvant treatment is given. Neoadjuvant imatinib may increase the cure rate by shrinking large GISTs and preserve organ function.Methods:We conducted an Asian multinational phase II study for patients with gastric GISTs ≥10 cm. Patients received neoadjuvant imatinib (400 mg/day) for 6-9 months. The primary end point was R0 resection rate.Results:A total of 56 patients were enroled in this study. In the full analysis set of 53 patients, neoadjuvant imatinib for ≥6 months was completed in 46 patients. Grade 3-4 neutropenia and rash occurred in 8% and 9%, respectively, but there were no treatment-related deaths. The response rate by RECIST was 62% (95% CI, 48-75%). The R0 resection rate was 91% (48/53) (95% CI, 79-97%). Preservation of at least half of the stomach was achieved in 42 of 48 patients with R0 resection. At the median follow-up time of 32 months, 2-year overall and progression-free survival rates were 98% and 89%, respectively.Conclusions:Neoadjuvant imatinib treatment for 6-9 months is a promising treatment for large gastric GISTs, allowing a high R0 resection rate with acceptable toxicity.

Original languageEnglish
Pages (from-to)25-32
Number of pages8
JournalBritish journal of cancer
Volume117
Issue number1
DOIs
Publication statusPublished - Jun 27 2017

Fingerprint

Gastrointestinal Stromal Tumors
Stomach
Neoadjuvant Therapy
Exanthema
Neutropenia
Disease-Free Survival
Imatinib Mesylate
Therapeutics
Survival Rate

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Kurokawa, Y., Yang, H. K., Cho, H., Ryu, M. H., Masuzawa, T., Park, S. R., ... Kang, Y. K. (2017). Phase II study of neoadjuvant imatinib in large gastrointestinal stromal tumours of the stomach. British journal of cancer, 117(1), 25-32. https://doi.org/10.1038/bjc.2017.144

Phase II study of neoadjuvant imatinib in large gastrointestinal stromal tumours of the stomach. / Kurokawa, Yukinori; Yang, Han Kwang; Cho, Haruhiko; Ryu, Min Hee; Masuzawa, Toru; Park, Sook Ryun; Matsumoto, Sohei; Lee, Hyuk Joon; Honda, Hiroshi; Kwon, Oh Kyoung; Ishikawa, Takashi; Lee, Kyung Hee; Nabeshima, Kazuhito; Kong, Seong Ho; Shimokawa, Toshio; Yook, Jeong Hwan; Doki, Yuichiro; Im, Seock Ah; Hirota, Seiichi; Hahn, Seokyung; Nishida, Toshirou; Kang, Yoon Koo.

In: British journal of cancer, Vol. 117, No. 1, 27.06.2017, p. 25-32.

Research output: Contribution to journalArticle

Kurokawa, Y, Yang, HK, Cho, H, Ryu, MH, Masuzawa, T, Park, SR, Matsumoto, S, Lee, HJ, Honda, H, Kwon, OK, Ishikawa, T, Lee, KH, Nabeshima, K, Kong, SH, Shimokawa, T, Yook, JH, Doki, Y, Im, SA, Hirota, S, Hahn, S, Nishida, T & Kang, YK 2017, 'Phase II study of neoadjuvant imatinib in large gastrointestinal stromal tumours of the stomach', British journal of cancer, vol. 117, no. 1, pp. 25-32. https://doi.org/10.1038/bjc.2017.144
Kurokawa, Yukinori ; Yang, Han Kwang ; Cho, Haruhiko ; Ryu, Min Hee ; Masuzawa, Toru ; Park, Sook Ryun ; Matsumoto, Sohei ; Lee, Hyuk Joon ; Honda, Hiroshi ; Kwon, Oh Kyoung ; Ishikawa, Takashi ; Lee, Kyung Hee ; Nabeshima, Kazuhito ; Kong, Seong Ho ; Shimokawa, Toshio ; Yook, Jeong Hwan ; Doki, Yuichiro ; Im, Seock Ah ; Hirota, Seiichi ; Hahn, Seokyung ; Nishida, Toshirou ; Kang, Yoon Koo. / Phase II study of neoadjuvant imatinib in large gastrointestinal stromal tumours of the stomach. In: British journal of cancer. 2017 ; Vol. 117, No. 1. pp. 25-32.
@article{a2ac492ef8994dc7975eab7f3dff17e1,
title = "Phase II study of neoadjuvant imatinib in large gastrointestinal stromal tumours of the stomach",
abstract = "Background:Gastrointestinal stromal tumours (GISTs) with high-risk features have poor prognosis even if adjuvant treatment is given. Neoadjuvant imatinib may increase the cure rate by shrinking large GISTs and preserve organ function.Methods:We conducted an Asian multinational phase II study for patients with gastric GISTs ≥10 cm. Patients received neoadjuvant imatinib (400 mg/day) for 6-9 months. The primary end point was R0 resection rate.Results:A total of 56 patients were enroled in this study. In the full analysis set of 53 patients, neoadjuvant imatinib for ≥6 months was completed in 46 patients. Grade 3-4 neutropenia and rash occurred in 8{\%} and 9{\%}, respectively, but there were no treatment-related deaths. The response rate by RECIST was 62{\%} (95{\%} CI, 48-75{\%}). The R0 resection rate was 91{\%} (48/53) (95{\%} CI, 79-97{\%}). Preservation of at least half of the stomach was achieved in 42 of 48 patients with R0 resection. At the median follow-up time of 32 months, 2-year overall and progression-free survival rates were 98{\%} and 89{\%}, respectively.Conclusions:Neoadjuvant imatinib treatment for 6-9 months is a promising treatment for large gastric GISTs, allowing a high R0 resection rate with acceptable toxicity.",
author = "Yukinori Kurokawa and Yang, {Han Kwang} and Haruhiko Cho and Ryu, {Min Hee} and Toru Masuzawa and Park, {Sook Ryun} and Sohei Matsumoto and Lee, {Hyuk Joon} and Hiroshi Honda and Kwon, {Oh Kyoung} and Takashi Ishikawa and Lee, {Kyung Hee} and Kazuhito Nabeshima and Kong, {Seong Ho} and Toshio Shimokawa and Yook, {Jeong Hwan} and Yuichiro Doki and Im, {Seock Ah} and Seiichi Hirota and Seokyung Hahn and Toshirou Nishida and Kang, {Yoon Koo}",
year = "2017",
month = "6",
day = "27",
doi = "10.1038/bjc.2017.144",
language = "English",
volume = "117",
pages = "25--32",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Phase II study of neoadjuvant imatinib in large gastrointestinal stromal tumours of the stomach

AU - Kurokawa, Yukinori

AU - Yang, Han Kwang

AU - Cho, Haruhiko

AU - Ryu, Min Hee

AU - Masuzawa, Toru

AU - Park, Sook Ryun

AU - Matsumoto, Sohei

AU - Lee, Hyuk Joon

AU - Honda, Hiroshi

AU - Kwon, Oh Kyoung

AU - Ishikawa, Takashi

AU - Lee, Kyung Hee

AU - Nabeshima, Kazuhito

AU - Kong, Seong Ho

AU - Shimokawa, Toshio

AU - Yook, Jeong Hwan

AU - Doki, Yuichiro

AU - Im, Seock Ah

AU - Hirota, Seiichi

AU - Hahn, Seokyung

AU - Nishida, Toshirou

AU - Kang, Yoon Koo

PY - 2017/6/27

Y1 - 2017/6/27

N2 - Background:Gastrointestinal stromal tumours (GISTs) with high-risk features have poor prognosis even if adjuvant treatment is given. Neoadjuvant imatinib may increase the cure rate by shrinking large GISTs and preserve organ function.Methods:We conducted an Asian multinational phase II study for patients with gastric GISTs ≥10 cm. Patients received neoadjuvant imatinib (400 mg/day) for 6-9 months. The primary end point was R0 resection rate.Results:A total of 56 patients were enroled in this study. In the full analysis set of 53 patients, neoadjuvant imatinib for ≥6 months was completed in 46 patients. Grade 3-4 neutropenia and rash occurred in 8% and 9%, respectively, but there were no treatment-related deaths. The response rate by RECIST was 62% (95% CI, 48-75%). The R0 resection rate was 91% (48/53) (95% CI, 79-97%). Preservation of at least half of the stomach was achieved in 42 of 48 patients with R0 resection. At the median follow-up time of 32 months, 2-year overall and progression-free survival rates were 98% and 89%, respectively.Conclusions:Neoadjuvant imatinib treatment for 6-9 months is a promising treatment for large gastric GISTs, allowing a high R0 resection rate with acceptable toxicity.

AB - Background:Gastrointestinal stromal tumours (GISTs) with high-risk features have poor prognosis even if adjuvant treatment is given. Neoadjuvant imatinib may increase the cure rate by shrinking large GISTs and preserve organ function.Methods:We conducted an Asian multinational phase II study for patients with gastric GISTs ≥10 cm. Patients received neoadjuvant imatinib (400 mg/day) for 6-9 months. The primary end point was R0 resection rate.Results:A total of 56 patients were enroled in this study. In the full analysis set of 53 patients, neoadjuvant imatinib for ≥6 months was completed in 46 patients. Grade 3-4 neutropenia and rash occurred in 8% and 9%, respectively, but there were no treatment-related deaths. The response rate by RECIST was 62% (95% CI, 48-75%). The R0 resection rate was 91% (48/53) (95% CI, 79-97%). Preservation of at least half of the stomach was achieved in 42 of 48 patients with R0 resection. At the median follow-up time of 32 months, 2-year overall and progression-free survival rates were 98% and 89%, respectively.Conclusions:Neoadjuvant imatinib treatment for 6-9 months is a promising treatment for large gastric GISTs, allowing a high R0 resection rate with acceptable toxicity.

UR - http://www.scopus.com/inward/record.url?scp=85021443124&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021443124&partnerID=8YFLogxK

U2 - 10.1038/bjc.2017.144

DO - 10.1038/bjc.2017.144

M3 - Article

C2 - 28535156

AN - SCOPUS:85021443124

VL - 117

SP - 25

EP - 32

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 1

ER -